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INTRODUCTION
Attention Deficit/Hyperactivity Disorder (ADHD) is the most common neurodevelopmental
alteration in childhood (Curatolo et al., 2009; Purper-Ouakil et al., 2011) characterized by pervasive
and impairing symptoms of inattention, hyperactivity, and impulsivity, which often lead to
poor academic performance and impaired social interactions (American Psychiatric Association,
2000). The estimated world prevalence for ADHD is around 5% (Polanczyk et al., 2007), with
an onset during childhood of symptoms that often persist into adolescence and adulthood
(Biederman et al., 2006).
Although the etiology of ADHD is multi-factorial, this syndrome is viewed as a motivational
dysfunction. Several neuroimaging and neurophysiological studies have shown a delay in the
normal brain development and functional abnormalities in brain areas related to executive
functions (Shaw et al., 2013; Hart et al., 2014; Rubia et al., 2014), reporting evidence of
imbalanced prefrontal and/or striatal levels of neurotransmitters, especially dopamine (Oades,
1998; Sagvolden and Sergeant, 1998) and altered cross-talk between fronto-striatal circuits
(Chambers and Potenza, 2003).
Twin, family and adoption studies have supported a strong genetic base for the disorder,
with heritability ranging from 60 to 90% (Goodman and Stevenson, 1989; Biederman et al.,
1990; Levy et al., 1997). Pre-, peri-, and postnatal environmental factors play an important role.
Maternal lifestyle during pregnancy and parent-infant interactions have been proposed to affect
the phenomenological expression, resulting in a more, or less severe constellation of symptoms
(Milberger et al., 1996; Coffin et al., 2005; Neuman et al., 2007).
For the identification of genes involved in ADHD, several studies have been conducted (Li et al.,
2006; Wood and Neale, 2010), but to date no determinant genetic marker has been identified.
ADHD candidate genes have been hypothesized, including dopamine and serotonin transporters
and the dopamine D4 and D5 receptors (Klein et al., 2017).
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DAT1 GENE AND ITS
EPIGENETIC MODULATION
Recent research has focused on the dopamine transporter (DAT)
because modifications in the expression and/or function of this
gene may well lead to ADHD symptoms (Bannon, 2005; Jucaite
et al., 2005). Furthermore, subjects with ADHD respond well
to drugs that inhibit DAT, including methylphenidate. DAT1
polymorphisms have also been associated with other psychiatric
disorders like generalized anxiety, social phobia, obsessive-
compulsive disorder, and Tourette’s (Rowe et al., 1998; Gadow
et al., 2008).
DAT1 gene has a 40 bp variable number tandem repeat
(VNTR) in the 3’-untranslated region, which exist in 3–13 copies;
the 9–10-repetition alleles are the most common. Although not
all literature agrees, the 10-R allele has often been implicated in
the presentation of ADHD (Cook et al., 1995; Gill et al., 1997;
Waldman et al., 1998; Curran et al., 2001).
Epigenetic study supports a pivotal role in neuronal
development, differentiation, cell communication, and
synaptic plasticity (Levenson and Sweatt, 2006). Among
epigenetic mechanisms, the methylation of DNA (leading
to gene silencing) is the best characterized and studied.
DNA methylation mostly occurs in the promoter CpG
islands, where the bases converted to 5-methylcytosine,
directly exert negative effects on the expression of genes.
DNA methylation has been recently implicated in the
development of psychiatric disorders, such as bipolar
disorder, depression, and schizophrenia (D’Addario et al.,
2012, 2013, 2017). Despite the abnormal methylation of
promoter-specific CpG residues could be considered as a stable
signature in complex psychiatric disorders, the association
between DNA methylation level and a given disease is quite
inconsistent. For instance, both increased and unchanged level
of methylation were highlighted in patients with schizophrenia
(Bromberg et al., 2008; Carrard et al., 2011).
DAT1 METHYLATION
ANALYSIS—PREVIOUS DATA
Recently, in order to highlight objective biomarkers useful for
the diagnosis of ADHD, some research has focused on DNA
methylation in the promoter of DAT1 gene. Xu et al. (2015)
examined the association of such epigenetic marker with ADHD
among Chinese Han children. In his study, which compared
50 ADHD patients with 50 non-ADHD control subjects, a
prominent decrease was shown in DAT1 and other dopaminergic
genes DRD4 and DRD5, highlighting a severely restricted
dopaminergic system in children with ADHD. In order to verify
whether the alterations in DAT1 expression were caused by
CpG methylation, Xu et al. searched for a CpG island located
in the 5’-UTR, a gene regulation area, identifying 19 CpG
sites. Subsequently, the methylation status of these sites was
analyzed using bisulfite sequencing. Their results reveal three
individual CpG sites (site 7, 8, and 18 in authors’ numeration)
that showed a significant difference in methylation compared to
the control group.
We (Adriani et al., 2018) similarly assessed the epigenetic
status of the 5’-UTR region of DAT1 gene. We recruited
school-aged children (6–12 years old) diagnosed by routine
anamnestic and cognitive evaluation, plus Conners’ scales and
k-SADS. None of them was a smoker. In general, altered
methylation levels were found for six selected CpG sites, for
ADHD patients compared to healthy controls. To support this
hypothesis, we analyzed the correlation between the subjects’
clinical scores and methylation data. We found that hyper-
methylation in CpG M1 correlated negatively with CGAS
(Children’s Global Assessment Scale) value, and slightly with
some of the Conners’ subscales, thus serving an index of severity
for ADHD. Whereas, hyper-methylation in CpG M6 correlated
with change of CGAS and Conners’ after 6 weeks of therapy,
thus serving an index of likelihood for therapeutic efficacy.
Interestingly the CpG M5 turned out to be correlated with M6
on one side, and with M1, M2, M3 on the other hand (see also
Lambacher et al., 2020).
However, the crucial question was whether the CpG residues
we identified were more relevant compared to these identified by
Xu et al. (2015). Figure 1 shows the entire DNA sequence of the
5’-UTR region of the DAT, highlighting the areas examined by Xu
et al. (2015) and by our previous study (Adriani et al., 2018).
Studies on the DAT1 gene have also been conducted in
the research of biomarkers for Tourette syndrome (Müller-Vahl
et al., 2017) highlighting an altered DAT methylation in the
most severely affected patients. However, the DNA sequence
analyzed in this study is before TSS (where mRNA starts) thus
not including the 5’-UTR.
A NEW CONTRIBUTOR:OPPOSITE-
STRAND METHYLATION LEVEL
It should be considered that the fidelity of maintenance
of CpG methylation within cell division has been found
to be very high in hemi-methylated DNA, on the other
hand de novo methylation resulted to be quite low (Riggs
et al., 1998). Dnmt3a and Dnmt3b methylate DNA de novo,
and this occurs without regard to the methylation status of
the complementary CpG position (Okano et al., 1998). It
should also be considered that within each CpG dyad, several
enzymes (i.e., DNMT-TET-TDG) could theoretically control
as many as 21 cytosine modification states not necessarily in
symmetric form (Wu and Zhang, 2014). We thus thought
of relevance the evaluation of the reverse strand in order
to monitor a possible differential methylation in the two
strands in ADHD subjects. For this reason, extending the work
previously done (Adriani et al., 2018), we run a new assay for
methylation levels on the other strand, which is just facing
the previously assessed strand: in other words, we thought of
analyzing methylation levels of CpG residues, which are exact
complementary on opposite strand (“cos”) to the previous, already
assessed ones.
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FIGURE 1 | DNA sequence of DAT gene 5’-UTR. The sequence highlighted in orange is that examined by Xu et al. (2015). The area highlighted in blue is the one
examined in our previous study (Adriani et al., 2018). The blue CpG islands are those that are likely to be methylated, whereas the red “K” are the specific cytosines
that the two studies report to be hyper methylated in ADHD. The inset (below) provides a further detail of the blue-highlighted area, together with its complementary
sequence on the opposite strand (reported as forward strand, from its 5’ to its 3’) and CpG numerations. COS, complementary on the opposite strand.
We selected 14 ADHD patients (half 9\10 and half 10\10
genotype) for which we assessed the other strand (Figure 1).
Once new data available, we performed correlations on
methylation levels, expressed as percentage of methylated CpG
in the sample: we correlated the newly assessed CpGs (termed
from M7-cos to M1-cos) among them and also between all them
and old CpGs. The results are shown on Table 1. The M5-cos is
correlated with M6-cos whereas the M1-cos, M2-cos, and M3-
cos are all strongly correlated one to each other: the profile on
the opposite strand is identical to that found for the gene strand
(see Lambacher et al., 2020). Moreover, the M6-cos is negatively
correlated to M6 while the M1-cos is negatively correlated to M2.
The M7 and the M7-cos, although some results were evident, are
not taken here in consideration as the original data only point to
M1, M2, and M6; therefore, we focused on the functional motifs
CGGCGGCGG (M1–M3) and CGCG (M5 plus M6).
These new data suggest that not only M1, M2, and M6 located
on the same strand of the gene are important: also the M1-cos
and M6-cos located on the opposed strand are crucial. While
increased M1 (or M2\M6) methylation on the strand of the gene
is associated with ADHD (or its relief), very intriguingly the same
sites tend to be demethylated on the opposed strand. This is the
first time (at least to our knowledge) that the importance of the
opposed strand is claimed as important for the role of a given
gene within a given pathology.Whereby a CpG residue is claimed
important when its methylation is increased, the corresponding
CpG residue on the opposed strand might be claimed important
when its methylation is conversely decreased.
A NEW APPROACH TO CPG STUDIES
We thought that, if crucial CpG positions exist, these shall
be ON (Methylated) on one (gene) strand and moreover OFF
(Demethylated) on the other (opposed) strand. The quantity
of CpGs in any DNA trait is 1\16 of total, based on simple
probability: it is unlikely that all of them are equally crucial.
We propose that the identification of a crucial CpG, to cause
a given phenotype, may exploit its negative correlation with its
complementary opposite.
For first motif CGGCGGCGG the best candidates are M1
and M2; for second motif CGCG the best candidate is M6. By
doing this kind of reasoning, we realized that the relevance of
M2 and M1-cos, suggested by their being highly correlated (see
Table 1), is supported by their being also physically close on
the DNA. The cytosine of M2 is indeed close to the cytosine of
M1-cos (more than cytosine of M2-cos is with cytosine of M1).
As such, where two or more CpGs form a motif, we postulate
the following possibility for a functional interaction: given one
candidate cytosine (e.g., CpG 2), the leftward opposed cytosine
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TABLE 1 | Correlation among the newly assessed CpGs and between all the new
CpGs vs. all the old CpGs.
CpG CpG CpG CpG CpG CpG CpG
M7-cos M6-cos M5-cos M4-cos M3-cos M2-cos M1-cos
co M6-cos −0.071
co M5-cos −0.018 0.709
co M4-cos 0.15 0.525 0.799
co M3-cos 0.013 0.382 0.397 0.351
co M2-cos −0.075 0.307 0.43 0.527 0.599
co M1-cos −0.032 0.467 0.356 0.191 0.71 0.691
co M7 −0.174 −0.198 −0.274 −0.157 −0.1 −0.31 −0.384
co M6 −0.18 −0.421 −0.145 0.006 0.184 0.053 −0.249
co M5 −0.274 0.045 0.014 0.086 0.225 0.083 −0.082
(M4) N/A
co M3 −0.561 −0.066 −0.03 −0.053 0.01 −0.031 −0.131
co M2 −0.159 0.11 0.162 0.173 −0.302 −0.018 −0.447
co M1 −0.03 0.045 −0.151 −0.034 0.177 0.289 0.08
Pink highlights denote correlation values higher than 0.6411. Green highlights denote the
newly discovered negative correlation.
The M1-cos, M2-cos, and M3-cos are all strongly correlated one to each other. The
M5-cos is correlated only with M6-cos.
TheM6-cos is negatively correlated to M6while the M1-cos is negatively correlated toM2.
M2 and M1-cos are also physically close on the DNA: a given protein may interact
with both, well before the two DNA strands are opened for mRNA transcription.
Data, given one candidate cytosine, point to the leftward opposed cytosine (facing the
preceding guanine in a motif on that same strand).
It is suited as well to serve a biomarker if compared with the direct opposed cytosine
(rightward, facing the following guanine).
(i.e., CpG 1-cos), facing the guanine of the CpG just preceding the
candidate one on that same strand, is as well-suited if compared
with the directly opposed cytosine (i.e., CpG 2-cos), which is
anyway rightward since it’s facing the guanine following the
candidate cytosine. Following similar reasoning, the use of M6
and M5-cos should be suggested: despite the fact that these two
are not correlated (see Table 1), yet they are physically close on
the DNA. The cytosine of M6 is indeed very close to the cytosine
of M5-cos (more than cytosine of M6-cos is with cytosine of M6
itself, perhaps).
In order to construct an index, to be then used for clinical
purposes, two or more parameters may well be multiplied
if they co-vary with the pathology in the same direction.
For instance we proposed to multiply methylation with level
of DAT-directed auto-antibody (Adriani et al., 2018). Given
negative correlations between strands, corresponding residues
on the other (cos) strand could be used as well, but they anti-
covary: therefore, they could be considered as contributing for
the proportion of demethylation. Therefore, the index should
multiply the methylation level for gene-strand CpGs with≪100
– methylation≫ for any CpG-cos (see Lambacher et al., 2020).
CONCLUSION AND FUTURE
PERSPECTIVES
To date, clinical diagnosis of ADHD is solely based on structured
interviews or on questionnaires; as such, risk of subjectivity
in the interpretation of outcomes may give rise to doubts
about their diagnostic reliability. Previous studies have shown
that the determination of DNA methylation in specific CpG
residues within the 5’-UTR region of the DAT1 gene can be
used as reliable indicator of ADHD (Giana et al., 2015; Adriani
et al., 2018). Also, research showed the role of conventional
epigenetic components in ADHD, such as MeCP2, histone
transferacetylases and de-acetylases. Few critical methylated CpG
sites in the DRD4 promoter also exhibit a considerably different
pattern in ADHD children, compared to healthy controls
(Xu et al., 2015; Dadds et al., 2016).
The purpose of this commentary was to provide an overview
about a new possible approach, when searching an epigenetic
biomarker for ADHD. Our data presented here suggest indeed
a new approach to DNA methylation analysis. Our hypothesis,
accordingly, is that the methylation levels on the strand opposed
to the candidate gene can be used to identify which CpG sites,
on the gene-strand, are really crucial; this, may strengthen their
correlations with clinical data.
This is the first time, to our knowledge, that the importance of
the opposed strand is claimed. We are suggesting that patterns
of methylation on the strand of the gene, specifically for CpG
sites M1, M2, and M6 associated with ADHD, establish an
unsuspected relationship with patterns of decreased methylation
on the opposed strand. This hypothesis clearly needs more
studies, which should further assess the level of methylation
in many more of the opposite CpG residues. The main limit
of studies on ADHD biomarkers is the relatively small size of
clinical samples, suggesting to deepen the research with further
studies on larger samples. More in general, we are suggesting to
evaluate this complementary-strand aspect in all next studies on
DNA methylation.
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